Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06127199 · ClinicalTrials.gov registry record · NA
Contraceptive Efficacy Study of Ovaprene
A NA study of Contraception, sponsored by Daré Bioscience.
- Recruiting
- Registry status
- NA
- Development phase
- 656
- Enrollment target
- 20
- Study locations
NCT06127199: Recruiting NA study of Contraception, sponsored by Daré Bioscience.
NCT06127199 is a NA study of Contraception that is actively recruiting participants, run by Daré Bioscience. The registered enrollment target is 656 participants, above the 446-participant average among 72 other Contraception trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06127199, a NA study of Contraception, is actively recruiting participants, sponsored by Daré Bioscience.
- RECRUITING
- Registry status
- NA
- Development phase
- 656 participants
- Enrollment target
- 20
- Study locations
Study Summary
This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.
Primary Outcome
Measurement of number of pregnancies over 13 menstrual cycles (13-cycle Pearl Index)
Conditions Studied
Interventions
- DEVICE Ovaprene
Study Locations (20)
California
- Essential Health Access (Berkeley) - Berkeley
- Essential Access Health - Los Angeles
- Amicis Research Center - Newhall
- University of California at Davis - Sacramento
- University of California, San Francisco - San Francisco
Arizona
- Precision Trials AZ - Phoenix
- MomDoc Women's Health Research - Scottsdale
- Del Sol Research Management, LLC - Tucson
New York
- Columbia University - New York
- Einstein College of Medicine - The Bronx
Colorado
- University of Colorado Denver - Aurora
Georgia
- Emory University - Atlanta
Hawaii
- University of Hawaii - Honolulu
Louisiana
- Praetorian Pharmaceutical Research, LLC - Marrero
Maryland
- The Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 656 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT06127199 shows while recruiting
NCT06127199 is an interventional study that assigns participants to a tested intervention. The registered 656 participants enrollment target is mid-sized for trials with a published cap, above the 446-participant average among 72 other Contraception trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Ovaprene is the first listed.
NCT06127199 names 20 study sites across 13 states, led by California, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT06127199 about?
NCT06127199 is a clinical study titled "Contraceptive Efficacy Study of Ovaprene". This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability of Ovaprene.
What is the current status of trial NCT06127199?
This trial is currently recruiting. It is a NA study. The enrollment target is 656 participants. The study started on 2023-12-19. Estimated completion is 2026-09.
What conditions does trial NCT06127199 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT06127199?
The interventions under investigation include: Ovaprene (DEVICE).
Who is sponsoring clinical trial NCT06127199?
This trial is sponsored by Daré Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06127199 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06127199's enrollment target sits among peer trials
656 17th of 72 higher than 56 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
-
Patient-centered Information on Permanent Contraception
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI